Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Clinical Trial

Official title:

Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03159819
• Other study ID #: CG4003
• Status: Recruiting
• Phase: N/A
• First received: May 11, 2017
• Last updated: March 8, 2018
• Start date: April 1, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: March 2018
• Source: Changhai Hospital
• Contact: Xianbao Zhan, M.D.
• Phone: 86-021-31161441
• Email: zhanxianbao[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single arm, open-label pilot study is designed to determine the safety, tolerability and engraftment of CAR-CLD18 T cells in patients with advanced gastric adenocarcinoma and pancreatic adenocarcinoma.

Description:

For patients with gastric adenocarcinoma who have not been cured with first line chemotherapy, and who are not willing to undergo second line chemotherapy after the failure of first line chemotherapy while there are no effective therapies for their unmet medical needs known at this time, and for patients with advanced/metastatic pancreatic adenocarcinoma which has relapsed after surgery or for which there is no surgical indication, who have not been cured with or refused to receive other standard regimens, single or multiple doses of CAR-CLD18 T cells will be given to observe safety and efficacy of CAR-CLD18 T cells.

Primary objectives:

Determine the safety, tolerability and cytokinetics of the autologous T cells transduced with anti-Claudin18.2 lentiviral vector in patients with gastric adenocarcinoma and pancreatic adenocarcinoma.

Secondary objectives:

Make a preliminary evaluation on the efficacy of CAR-CLD18 T cells in patients with gastric adenocarcinoma and pancreatic adenocarcinoma with the following parameters:

Time of tumor progression (TTP);

Disease Control Rate (DCR);

Objective Remission Rate (ORR);

Overall Survival (OS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patients aged 18 - 70 with pathologically confirmed advanced gastric adenocarcinoma and pancreatic adenocarcinoma.

2. Biopsy confirmation of Claudin18.2 positive.

3. Patients with advanced gastric adenocarcinoma who have not been cured with second line chemotherapy, and who are not willing to undergo second line chemotherapy after the failure of first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.

4. Patients with advanced/metastatic pancreatic adenocarcinoma which has relapsed after surgery or for which there is no surgical indication, who have not been cured with or refused to receive other standard regimens.

5. Expected survival after first dose of study drug > 12 weeks.

6. At least one measurable lesion (= 10 mm) for imaging assessment.

7. ECOG scores 0 - 1.

8. Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.

9. White blood cells (WBCs) = 2.5×10^9/L Platelets (PLT) = 100×10^9/L Hemoglobin, Blood (Hb) = 9.0 g/dL MID = 1.5×10^9/L Lymphocyte (LY) = 0.47×10^9/L LY% = 15%

10. Serum albumin (Alb) = 30 g/L

11. Serum lipase (LPS) and serum amylase < 1.5 ULN

12. Serum creatinine = 1.5 ULN

13. Alanine aminotransferase (ALT) = 2.5 ULN Aspartate aminotransferase (AST) = 2.5 ULN If osseous metastasis or liver metastasis is developed and alkaline phosphatase (ALP) > 2.5 ULN, ALT and AST < 1.5 ULN.

14. Serum total bilirubin (TBIL) = 1.5 ULN

15. Prothrombin Time (PT): International Normalized Ratio (INR) < 1.7. PT < (ULN + 4) s

All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.

Exclusion Criteria:

• Patients with any of the following conditions are not eligible for the study.

1. Pregnant or lactating women.

2. HIV positive, HCV positive, HBV DNA copies = 10^3.

3. Uncontrolled active infection.

4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.

5. Allergic to immunotherapies and related drugs.

6. Untreated brain metastases or having symptoms of brain metastases.

7. Metastases to the lung: central tumor or multiple metastases.

8. Patients with heart disease for which treatment is needed or with poorly controlled hypertension.

9. Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.

10. Patients with previous organ transplantation or in preparation for organ transplantation.

11. Patients in need of anticoagulant treatment (e.g. warfarin or heparin).

12. Patients in need of long-term antiplatelet treatment (aspirin, dosage > 300 mg/d; clopidogrel, dosage > 75 mg/d).

13. Previous treatment with chemoradiotherapy and tumor-targeting drug which were conducted 4 weeks prior to the study (blood collection).

14. Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.

15. The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.

Related Conditions & MeSH terms

• Adenocarcinoma
• Advanced Gastric Adenocarcinoma
• Pancreatic Adenocarcinoma

Intervention

Genetic:
• CAR-CLD18 T Cells
Dose escalation will be applied in this study.

Locations

Country	Name	City	State
China	Changhai Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Changhai Hospital	Carsgen Therapeutics, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Anti-tumor responses to CAR-CLD18 T cell infusions	Disease Control Rate (DCR)	2 years
Other	Anti-tumor responses to CAR-CLD18 T cell infusions	Progression-free Survival (PFS)	2 years
Other	Anti-tumor responses to CAR-CLD18 T cell infusions	Time of Tumor Progression (TTP)	2 years
Other	Anti-tumor responses to CAR-CLD18 T cell infusions	Overall Survival (OS)	2 years
Primary	Safety and tolerance	During the trial conduction, especially within the 24 weeks of treatment phase when CAR-CLD18 T cell administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all = grade 3 adverse events per CTCAE (v 3.0) will be recorded, including but not limited to the toxicities potentially suspected to relate to infusion procedures and/or CAR-CLD18 T cell therapy as listed below: Fever; Chills; Nausea, vomiting and other gastrointestinal symptoms; Fatigue; Hypotension; Respiratory distress; Tumor lysis syndrome; Cytokine release syndrome; Neutropenia, thrombocytopenia; Liver and kidney dysfunction	24 weeks
Secondary	Engraftment	Duration of in vivo survival of CAR-CLD18 T cells is defined as "engraftment". The primary engraftment endpoint is the number of DNA vector copies per mL blood of CAR-CLD18 T cells at regular intervals through week 4 following the initial infusion. Q-PCR for CAR-CLD18 T vector sequences will be performed until any 2 sequential tests are negative, documented as engraftment and persistence of CAR-CLD18 T cells.	2 years